New Age Metals (CVE:NAM) Trading Down 17.8% – What’s Next?
by Scott Moore · The Cerbat GemNew Age Metals Inc. (CVE:NAM – Get Free Report) shares traded down 17.8% during trading on Friday . The company traded as low as C$0.37 and last traded at C$0.37. 719,175 shares changed hands during trading, an increase of 581% from the average session volume of 105,542 shares. The stock had previously closed at C$0.45.
Wall Street Analysts Forecast Growth
Separately, Fundamental Research set a C$0.95 price objective on New Age Metals and gave the company a “buy” rating in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of C$0.95.
Read Our Latest Stock Analysis on NAM
New Age Metals Trading Down 17.8%
The company’s fifty day moving average price is C$0.36 and its two-hundred day moving average price is C$0.29. The company has a quick ratio of 17.88, a current ratio of 52.48 and a debt-to-equity ratio of 0.74. The company has a market cap of C$24.58 million, a price-to-earnings ratio of -61.67 and a beta of 0.08.
New Age Metals Company Profile
New Age Metals Inc, a mineral exploration company, engages in the acquisition, exploration, and development of platinum group metals (PGMs), and precious and base metal properties in Canada. The company explores for rhodium, palladium, platinum, gold, nickel, copper, and lithium deposits. It holds interests in the River Valley PGE project located in the Dana and Pardo townships of Northern Ontario; the Genesis PGE project located in south central Alaska; and lithium projects situated to the northeast of Winnipeg, Manitoba.
Recommended Stories
- Five stocks we like better than New Age Metals
- How to Invest in the Best Canadian Stocks
- Synopsys Sees Bullish Shift as Ansys Integration Drives Growth
- Overbought Stocks Explained: Should You Trade Them?
- The Best Holiday Present You Can Give Yourself? Costco Stock
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff